Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: Phase II study results

Clinical Genitourinary Cancer

Volumn 6, Issue 2, 2008, Pages 73-78

  Amato, Robert J ^a   Jac, Jaroslaw ^a   Hernandez Mcclain, Joan ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Hypoxia inducible factor; Moleculartargeted therapy; Simon 2 stage clinical trial; Thioredoxin reductase inhibitors

Indexed keywords

GADOLINIUM TEXAPHYRIN; METALLOPORPHYRIN;

ADULT; AGED; ANOREXIA; ARTICLE; BLISTER; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EVALUATION; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SKIN DISCOLORATION; DRUG ADMINISTRATION; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; METALLOPORPHYRINS; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 58149200520     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2008.n.011     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, et al. Cancer Facts & Figures 2008. American Cancer Society [Web site]. Available at: http://www.cancer.org/ downloads/STT/2008CAFFfinalsecured.pdf]. Accessed: September 11, 2008.
2. Amato R. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27: 177-86.
3. (Pubitemid 36910018) George D, Kaelin W. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003; 349: 419-21.
4. Godley P, Taylor M. Renal cell carcinoma. Curr Opin Oncol 2001; 13: 199-203.
5. Bleumer I, Oosterwijk E, De Mulder P, et al. Immunotherapy for renal cell carcinoma. Eur Urol 2003; 44: 65-75.
6. (Pubitemid 30261931) Motzer RJ, Mazumdar M, Bacik J, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 1928-35.
7. (Pubitemid 29368255) Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-40.
8. Linehan W, Zbar B, Bates S, et al. Cancer of the kidney and ureter. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 1362-96.
9. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-5.
10. (Pubitemid 32946535) Blancher C, Moore JW, Robertson N, et al. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF) -1 alpha, HIF-2 alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3 '-kinase/Akt signaling pathway. Cancer Res 2001; 61: 7349-55.
11. (Pubitemid 46089672) Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
12. (Pubitemid 46089673) Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
13. Bos R, van Diest PJ, de Jong JS, et al. Hypoxia-inducible factor-1 alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 2005; 46: 31-6.
14. (Pubitemid 32476461) Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 alpha (HIF-1 alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Bio 2001; 21: 3995-4004.
15. (Pubitemid 38448745) Zhong H, Semenza GL, Simons JW, et al. Up-regulation of hypoxia-inducible factor 1 alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004; 28: 88-93.
16. Lee YK, Strege AK, Bone ND, et al. Hypoxia inducible factor-1α is over expressed in CLL B cells because of an impaired proteasome pathway associated with defective interaction with von Hippel-Landau protein. Blood 2005; 106: 598a (Abstract 2115).
17. (Pubitemid 46849157) Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 3356: 2271-81.
18. (Pubitemid 34984438) Welsh S, Bellamy W, Briehl N, et al. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1 alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 2002; 2: 5089-95.
19. Welsh S, Williams R, Birmingham A, et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1 alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2003; 2: 235-43.
20. Hashemy SI, Ungerstedt JS, Avval FZ, et al. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 2006; 281: 10691-7.
21. Magda D, Lecane P , Cheryl L, et al. Motexafin gadolinium mobilizes zinc and inhibits thioredoxin reductase in human lymphoma cell lines. Blood 2004; 104: 164bm (Abstract 4316).
22. (Pubitemid 40616364) Magda D, Lecane P, Miller RA, et al. Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res 2005; 65: 3837-45.
23. (Pubitemid 32294318) Xu S, Zakian K, Thaler H, et al. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys 2001; 49: 1381-90.
24. Miller R, Fan Q, Lee I, et al. Motexafin gadolinium (MGd) increases tumor response to chemotherapy in Lewis lung cancer (LLC) animal model. Proc Am Soc Clin Oncol 2002; 21: 117a (Abstract 466).
25. (Pubitemid 32963846) Miller RA, Woodburn KW, Fan Q, et al. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res 2001; 7: 3215-21.
26. Lepp C, Qing F, Lecane P, et al. Motexafin gadolinium (MGd) enhances the activity of cisplatin, carboplatin, and docetaxel. AACR 2003; 44: 623-4.
27. Naumovski L, Bone N, Sirisawad M, et al. Motexafin gadolinium, a redox mediator, induces apoptosis in chronic lymphocytic leukemia B cells and is additive or synergistic with fludarabine. J Investig Med 2005; 53: S365.
28. Naumovski L, Chen J, Ramos J, et al. Inhibition of growth and induction of apoptosis by Motexafin gadolinium (Xcytrin (R)) alone and in combination with other therapeutic agents in lymphoma and myeloma tumor cell lines. Blood 2003; 102: 213b (Abstract 4573).
29. Naumovski L, Ramos J, Sirisawad M, et al. Potentiation of motexafin gadolinium cytotoxicity by celecoxib but not other cyclooxygenase-2 inhibitors. AACR 2005; 46: 1165.
30. Chen J, Ramos J, Sirisawad M, et al. Motexafin gadolinium enhances rituximab-induced cytotoxicity against B-cell lymphoma cell lines: role of elevated intracellular calcium. Blood 2005; 106: 287b (Abstract 4829).
31. (Pubitemid 29180823) Rosenthal DI, Nurenberg P, Becerra CR, et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999; 5: 739-45.
32. (Pubitemid 32702553) Carde P, Timmerman R, Mehta M P, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2000; 19: 2074-83.
33. (Pubitemid 46606335) Mehta M P, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003; 21: 2529-36.
34. Mehta M P, Gervais R, Chabot P, et al. Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: results of a phase III trial. J Clin Oncol 2006; 24 (18 suppl) : 367s (Abstract 7014).
35. (Pubitemid 30099779) Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
36. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
37. Common Terminology Criteria for Adverse Events (NCI CTCAE), version 3.0: National Cancer Institute Cancer Therapy Evaluation Program; 2006.
38. (Pubitemid 19099520) Simon R. Optimal two-stage design for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
39. Feldman DR, Kondagunta GV, Ronnen EA, et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2007; 25 (18 suppl) : 259s (Abstract 5099).
40. (Pubitemid 44780135) Magda D, Miller R. Motexafin gadolinium: a novel redux active drug for cancer therapy. Semin Can Bio 2006; 16: 466-76.
41. (Pubitemid 350296300) Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet 2007; 370: 2103-11.
42. Azad NS, Posadas EM, Kwitkowski VE, et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. J Clin Oncol 2006; 24 (18 suppl) : 121s (Abstract 3004).
43. Drabkin HA, Figlin RA, Stadler WM, et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment. J Clin Oncol 2007; 25 (18 suppl) : 245s (Abstract 5041).
44. Merchan JR, Liu G, Fitch T, et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol 2007; 25 (18 suppl) : 243s (Abstract 5034).
45. Rini BI, George DJ, Michaelson MD, et al. Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC). Ann Oncol 2006; 17: 144.
46. Sablin M P, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. J Clin Oncol 2007; 25 (18 suppl) : 244s (Abstract 5038).
47. (Pubitemid 46535711) Garcia J, Rini B. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007; 57: 112-25.
48. (Pubitemid 350296281) Motzer RJ, Basch E. Targeted drugs for metastatic renal cell carcinoma. Lancet 2007; 370: 2071-3.